Get to IND Faster

The industry standard from hit identification to development candidate nomination is on average 33-36 months. Charles River’s truly integrated drug discovery programs have reduced this timeline to as little as 24 months through industry experienced, multi-disciplinary teams focused on resource efficiency, scientific excellence and strategic partnerships with clients through all aspects of drug discovery. With numerous technologies for hit identification, coupled with our knowledge-based approach to advance compounds from hit-to-lead into lead optimization, our scientific advisory services team consistently convert leads into successful preclinical development candidates. Meet the Scientific Advisory Team

John Montana, PhD, Corporate Vice President, Integrated Drug Development and Strategic Projects, discusses the difference between an integrated drug discovery project and a traditional outsourcing project.

Understanding how and when to plan a preclinical investigational new drug (IND)-enabling program is an integral part of meeting specific milestones necessary for timely and efficient IND submission. Charles River has several decades of IND research experience, a unique range of services and best-in-class expertise to help clients successfully initiate and complete an IND-enabling program on time and within budget. Charles River supports clients in the design of suitable studies or programs for submission to all global regulatory authorities.
Learn more in our Investigational New Drug Development Programs eGuide